BMS Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Bristol Myer Reports Results of Orencia (abatacept) in P-IV Early AMPLE Study for Moderate-to-Severe Rheumatoid Arthritis #EULAR2019

Shots:

  • The P-IV Early AMPLE mechanistic study results involve assessing of Orencia (125 mg, SC) vs adalimumab (40mg, SC) on a background of MTX in 80 patients in a ratio (1:1) with moderate-to-severe RA seropositive for anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)
  • The P-IV Early AMPLE study results: @24wks. ACR 20/50/70 responses (83/70/48 vs 63/45/30); ACR 20/50/70 with Shared Epitope positive (SE+) (28.6/31.5/27.6); DAS28-CRP remission <2.6 (27.4), no new safety signals are observed
  • Orencia is an immunomodulator act by disrupting the continuous cycle of T-cell activation that characterizes RA and indicated for RA, juvenile idiopathic arthritis & adult psoriatic arthritis (PsA) in the US

Click here to read full press release/ article | Ref: BMS | Image: Dawson Design